Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: The last two decades have witnessed a rapid increase in the knowledge about the role of the orexin system, particularly in the regulation of wakefulness and arousal. Dual orexin receptor antagonists (DORAs) have been approved for the treatment of insomnia disorders (suvorexant, lemborexant) and drugs with a distinctive profile (daridorexant) or orexin-2 receptor selectivity (seltorexant) are in development. AREAS COVERED: This review discusses pharmacokinetics (PK), pharmacodynamics (PD), efficacy, and safety properties of orexin receptor antagonists (ORAs). EXPERT OPINION: In general, the drugs described have a similar effect on sleep characteristics although their pharmacokinetic variables differ. ORAs have the potential to revolutionize the pharmacological treatment of insomnia because they not only improve sleep, but, in addition, appear to have no dependence - and tolerance-inducing effects, which makes them suitable for long-term-treatment. The safety and tolerability profile of ORAs clearly differ from those of more traditional sleep-promoting drugs. Further research is needed to demonstrate benefits to patients suffering from insomnia disorder, e.g., with respect to improving not only sleep but also daytime functioning. In addition, ongoing and future research will show whether ORAs may have beneficial effects in patients with various psychiatric and neurodegenerative disorders, including Alzheimer's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sakurai, T., Amemiya, A., Ishii, M., Matsuzaki, I., Chemelli, R. M., Tanaka, H., Williams, S. C., Richardson, J. A., Kozlowski, G. P., Wilson, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)80949-6 · Cited by 5,501
The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity
de Lecea, L., Kilduff, T. S., Peyron, C., Gao, X.-B., Foye, P. E., Danielson, P. E., Fukuhara, C., Battenberg, E. L. F., Gautvik, V. T., Bartlett, F. S., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.1.322 · Cited by 3,878
Epidemiologic Study of Sleep Disturbances and Psychiatric Disorders: An Opportunity for Prevention?
Ford, D. E. (1989) · JAMA · doi:10.1001/jama.1989.03430110069030 · Cited by 2,252
European guideline for the diagnosis and treatment of insomnia
Riemann, D., Baglioni, C., Bassetti, C., Bjorvatn, B., Dolenc Groselj, L., Ellis, J. G., Espie, C. A., Garcia‐Borreguero, D., Gjerstad, M., Gonçalves, M., et al. (2017) · Journal of Sleep Research · doi:10.1111/jsr.12594 · Cited by 2,049
Qaseem, A., Kansagara, D., Forciea, M. A., Cooke, M., Denberg, T. D., & for the Clinical Guidelines Committee of the American College of Physicians* (2016) · Annals of Internal Medicine · doi:10.7326/m15-2175 · Cited by 1,965
Clinical Guideline for the Evaluation and Management of Chronic Insomnia in Adults
Schutte-Rodin, S., Broch, L., Buysse, D., Dorsey, C., & Sateia, M. (2008) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.27286 · Cited by 1,943
The hyperarousal model of insomnia: A review of the concept and its evidence
Riemann, D., Spiegelhalder, K., Feige, B., Voderholzer, U., Berger, M., Perlis, M., & Nissen, C. (2010) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2009.04.002 · Cited by 1,789
Sateia, M. J., Buysse, D. J., Krystal, A. D., Neubauer, D. N., & Heald, J. L. (2017) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.6470 · Cited by 1,519
The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness
Sakurai, T. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2092 · Cited by 1,276
Orexin A activates locus coeruleus cell firing and increases arousal in the rat
Hagan, J. J., Leslie, R. A., Patel, S., Evans, M. L., Wattam, T. A., Holmes, S., Benham, C. D., Taylor, S. G., Routledge, C., Hemmati, P., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.19.10911 · Cited by 1,234
Research works printed but not linked: 114
- 10.1007/s11065-011-9156-z · DOI
- 10.5665/SLEEP.1150 · DOI · Paper page
- 10.1176/appi.books.9780890425596 · DOI · Paper page
- 10.1016/S1474-4422(15)00021-6 · DOI · Paper page
- 10.1016/S1474-4422(13)70311-9 · DOI
- State-of-the-Science Conference NIH, 2005, NIH Cons State Sci Statements, 22, 1
- Insomnia RT, 2007, J Clin Sleep Med, 3, 7
- 10.3109/09540261.2014.888990 · DOI
- 10.1016/j.sleep.2010.02.018 · DOI · Paper page
- 10.1093/sleep/16.3.226 · DOI · Paper page
- Zammit GK, 1999, Sleep, 22, 379
- Balter MBUE, 1991, J Clin Psychiatry, 52, 16
- 10.1161/CIRCULATIONAHA.113.004500 · DOI · Paper page
- 10.1056/NEJMcp1412740 · DOI · Paper page
- 10.1016/j.sleh.2018.05.008 · DOI
- Benca RM, 2004, J Clin Psychiatry, 65, 26
- 10.7326/M15-1782 · DOI · Paper page
- Pigeon WR, 2007, J Clin Sleep Med, 3, 73
- 10.4088/PCC.v09n0105 · DOI · Paper page
- Holbrook AM, 2000, CMAJ, 162, 225
- Borbély AA, 1985, Hum Neurobiol, 4, 189
- Achermann P, 1987, Hum Neurobiol, 6, 203
- Taylor S, 2019, Public Health England, 89
- 10.5664/jcsm.26525 · DOI
- 10.1002/hup.594 · DOI · Paper page
- 10.1016/j.clinthera.2014.09.017 · DOI · Paper page
- 10.1016/j.sleep.2013.11.788 · DOI · Paper page
- 10.2165/00003495-200868130-00011 · DOI
- 10.4137/JCNSD.S1611 · DOI
- 10.5665/SLEEP.1272 · DOI · Paper page
- 10.4088/JCP.v69n1005 · DOI · Paper page
- 10.1016/S0166-2236(00)01594-0 · DOI · Paper page
- 10.3389/fnmol.2018.00220 · DOI · Paper page
- 10.1007/s40263-012-0036-8 · DOI
- 10.1038/nn.3810 · DOI · Paper page
- 10.1113/jphysiol.2011.217000 · DOI · Paper page
- 10.1016/j.neuron.2011.08.027 · DOI · Paper page
- 10.1111/j.1748-1716.2009.02056.x · DOI
- 10.1093/sleep/27.5.851 · DOI · Paper page
- 10.1378/chest.14-1617 · DOI · Paper page
- 10.1016/j.npep.2013.10.009 · DOI
- 10.1038/nm1544 · DOI · Paper page
- 10.1038/clpt.2010.19 · DOI
- 10.1038/clpt.2011.370 · DOI · Paper page
- 10.1016/S0304-3940(03)00066-1 · DOI
- 10.1371/journal.pone.0039131 · DOI · Paper page
- 10.1002/cmdc.201300003 · doi:10.1002/cmdc.201300003
- 10.1124/jpet.109.152009 · DOI · Paper page
- 10.3389/fnins.2014.00028 · DOI
- 10.1124/jpet.115.225466 · DOI
- 10.1177/0269881118773745 · DOI
- 10.1016/S0306-4522(01)00512-7 · DOI · Paper page
- 10.1523/JNEUROSCI.1887-05.2005 · DOI · Paper page
- 10.1021/jm100541c · DOI · Paper page
- 10.1111/ijcp.12568 · DOI · Paper page
- 10.3109/00498254.2015.1129565 · DOI
- 10.1002/jcph.785 · DOI
- 10.1002/cpt.1046 · DOI
- 10.1212/WNL.0b013e31827688ee · DOI · Paper page
- 10.1016/j.biopsych.2014.10.003 · DOI · Paper page
- 10.1016/S1474-4422(14)70053-5 · DOI · Paper page
- 10.1016/j.sleep.2015.10.007 · DOI
- 10.1016/j.sleep.2017.05.009 · DOI
- 10.5665/sleep.5168 · DOI
- 10.1007/s00213-016-4375-x · DOI · Paper page
- 10.1002/alz.12035 · DOI · Paper page
- 10.1093/sleep/zsz067.372 · doi:10.1093/sleep/zsz067.372
- 10.1017/cts.2018.167 · doi:10.1017/cts.2018.167
- 10.1089/cap.2019.0029 · DOI
- 10.1002/ams2.368 · DOI
- Hatta K, 2020, J Clin Psychiatry, 81, 19m12865
- 10.1007/s10388-017-0570-z · doi:10.1007/s10388-017-0570-z
- Toi N, 2019, J Clin Transl Endocrinol, 15, 37
- 10.1111/jch.13505 · DOI
- 10.1007/s40265-020-01276-1 · DOI
- Pastino G, 2015, Sleep, 38, A221
- 10.5664/jcsm.6800 · DOI · Paper page
- Thein SG, Alzheimer’s Assoc Int Conf 2019 July, 14–18
- Rosenberg R, 2019, JAMA, 2, e1918254
- 10.1016/j.sleep.2019.11.736 · doi:10.1016/j.sleep.2019.11.736
- 10.1017/S1092852920000802 · doi:10.1017/s1092852920000802
- Moline M, 2019, Sleep, 42, A150
- Eisai Co. Ltd. Eisai to present new 12-month safety & effectiveness data from phase 3 lemborexant SUNRISE 2 study and new patient and cohabitant insights about insomnia and toll on next-Day functioning at World Sleep Congress [Press release]. 2019 Sep 19.
- 10.1093/sleep/zsy260 · DOI · Paper page
- Zeitzer JM, 2020, JAMA, 3, e206614
- 10.5664/jcsm.8294 · DOI
- 10.1124/jpet.117.241596 · DOI
- 10.2174/1389200220666190206141814 · doi:10.2174/1389200220666190206141814
- 10.1016/j.euroneuro.2019.05.009 · DOI
- 10.1177/0269881119882854 · DOI
- 10.1097/JCP.0000000000001182 · DOI
- 10.1007/s00228-018-2559-5 · DOI
- 10.1111/1440-1681.13370 · DOI
- 10.1212/WNL.0000000000009475 · DOI
- 10.1002/ana.25680 · DOI
- Ltd I. Idorsia announces positive results in the first Phase 3 study of daridorexant with improved overall sleep and daytime performance of patients with insomnia [Press release]. 2020 Apr 20.
- 10.1177/0269881118791521 · DOI
- 10.1177/0269881118822258 · DOI
- 10.1038/s41398-019-0553-z · DOI · Paper page
- Minerva Neurosciences. Minerva Neurosciences announces achievement of primary and key secondary objectives in phase 2b clinical trial of seltorexant (MIN-202) in insomnia [Press release]. 2019 Jun 24.
- 10.1177/1715163514543856 · DOI
- 10.1046/j.1365-2125.1998.00764.x · DOI · Paper page
- 10.1001/jama.290.11.1500 · DOI · Paper page
- Dayal S, 2019, Clin Pharmacol Ther, 105, S.54
- 10.5664/jcsm.5382 · DOI
- 10.1002/kjm2.12130 · DOI
- Boof ML, Fietze I, Lederer K, et al. Effect of multiple-dose treatment with daridorexant on nighttime respiratory function in patients with mild and moderate obstructive sleep apnea (OSA). abstract #3058. ERS International Congress 2020. 2020. · doi:10.1183/13993003.congress-2020.2149
- 10.1093/sleep/30.3.312 · DOI · Paper page
- 10.2165/00003495-200363040-00004 · DOI
- 10.1016/j.rmed.2014.12.010 · DOI
- Boof ML, J Sleep Res, 2020
- 10.1093/sleep/zsz302 · DOI
- 10.1038/nm0507-526 · DOI
- 10.1038/s41386-020-0619-x · DOI
Cited by
De Crescenzo, F., D'Alò, G. L., Ostinelli, E. G., Ciabattini, M., Di Franco, V., Watanabe, N., Kurtulmus, A., Tomlinson, A., Mitrova, Z., Foti, F., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00878-9 · Cited by 446
Ozone, M., Hirota, S., Ariyoshi, Y., Hayashida, K., Ikegami, A., Habukawa, M., Ohshima, H., Harada, D., Hiejima, H., Kotorii, N., et al. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02811-2 · Cited by 24
Tachibana, M., Kanahara, N., Oda, Y., Hasegawa, T., Kimura, A., & Iyo, M. (2024) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.10946 · Cited by 17
Metadata
- Authors
- Muehlan, C., Vaillant, C., Zenklusen, I., Kraehenbuehl, S., & Dingemanse, J.
- Venue
- Expert Opinion on Drug Metabolism & Toxicology
- Publisher
- Informa UK Limited
- Published
- 2020-10-04
- Volume
- 16
- Issue
- 11
- Pages
- 1063-1078
- ISSN
- 1742-5255 (ISSN-L)
- 1744-7607
- OpenAlex
- W3084068073
- Cited by
- 102
- References
- 25
- FWCI
- 11.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders. https://app.cochat.ai/papers/10.1080/17425255.2020.1817380
- The paper
- Muehlan, C., Vaillant, C., Zenklusen, I., Kraehenbuehl, S., & Dingemanse, J. (2020). Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders. Expert Opinion on Drug Metabolism & Toxicology. https://doi.org/10.1080/17425255.2020.1817380
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.